Biotech Co.* (Symbol) | Pharma Co. (Symbol/Country) |
Type/Product Area |
Amount (M) |
Terms/Details (Date) |
Alteon Inc. (ALTN) | Taisho Pharmaceutical Co. Ltd.* (Japan) |
License agreement/Alteon's lead crosslink breaker, ALT-711 |
ND | Taisho was granted an exclusive option through 12/99 to acquire a license to ALT-711 for Japan, South Korea, Taiwan and China; financial details ND (9/99) |
Amylin Pharmaceuticals Inc. (AMLN) |
Linco Research Inc.* |
License agreement/Proprietary antibodies developed by Amylin | ND |
Amylin granted Linco exclusive rights for the use of its proprietary antibodies to develop immunoassay kits for the measurement of the hormones amylin and glucagonlike peptide; immunoassay kits developed by Linco may be manufactured and distributed by Linco; Amylin received an undisclosed credit to purchase kits or services from Linco; Amylin retains the right to use the licensed antibodies for its research activities (9/99) |
AnalytiCon AG* (Germany) | Bayer AG (Germany) | Research collaboration/AnalytiCon's separation and structure elucidation technologies | DM6 (US$3.18) | Analyticon will use its separation and structure elucidation technologies to isolate, purify and characterize novel natural products from biomaterials proprietary to Bayer (9/99) |
Antex Biologics Inc. (OTC BB: ANTX) | Pfizer Inc. (NYSE:PFE) |
Research collaboration/Antex's antigen receptor and nutriment signal details ND (9/99) |
ND |
Antex's platform technologies will be used by Pfizer for the development of animal vaccines; further transduction platform technologies |
ArQule Inc. (ARQL) |
Bayer Corp. (Germany) |
Research and development (R&D) collaboration/Arqule's Custom Array program |
$30 |
ArQule will produce compounds for screening against Bayer's therapeutic and agrochemical targets; Bayer will receive arrays designed to its specifications over a period of three years, and will own all rights to the compounds resulting from the collaboration; ArQule will receive $30M in cash payments over the term of the agreement as compound delivery goals are met (10/99) |
ArQule Inc. (ARQL) |
Pfizer Inc. (NYSE:PFE) |
Research and technology license agreement/Arqule's AMAP chemistry operating system | $117 |
ArQule will devote designated technologies, scientists and its AMAP system to generate compound libraries for Pfizer; ArQule could receive up to $117M over the 4.5-year term of the collaboration (7/99) |
Atugen Biotechnology GmbH* (Germany) |
AstraZeneca Group plc (UK; NYSE:AZN) | Research collaboration/Atugen's target validation services |
ND |
Astra will provide Atugen with gene targets and cell lines of interest for in vitro screening and delivery optimization; Atugen will develop GeneBloc reagents to knock down the genes of interest; Atugen will perform quantitative RNA analysis and technology transfers; Astra has the option to receive validated GeneBlocs against their targets for in vivo validation; financial terms ND (8/99) |
Avant Immunotherapeutics Inc. (AVAN) |
Pasteur Merieux Connaught (a unit of Rhone-Poulenc SA; France; NYSE:RP) |
Clinical trial collaboration/Avant's adjumer delivey system | ND | Avant and Pasteur will collaborate to evaluate the safety and immunogenicity of an adjumer-formulated respiratory syncytial virus vaccine in a Phase I trial; Avant previously received a milestone payment upon initiating the trial (8/99) |
Bio-Discovery Ltd.* (UK) |
ZymoGenetics Inc. (a Seattle-based subsidiary of Novo Nordisk A/S; Denmark; NYSE:NVO) |
Development agreement/Bio-Discovery's complement inhibitor B-D001 | ND | Bio-Discovery and ZymoGenetics signed an agreement to develop and commercialize Bio-Discovery's B-D001 for the prevention of reperfusion injury; Zymo receives a 12-month exclusive option period to evaluate the compound; if the option is exercised, Zymo would be responsible for funding all further clinical development and marketing; upon exercise of the option, Zymo would receive an exclusive, worldwide license to develop, manufacture and market B-D001 as a therapeutic agent; Bio-Discovery could receive undisclosed exercise fees, milestone payments and royalties (10/99) |
Bio-Technology General Corp. (BTGC) |
Teva Pharmaceutical Industries Ltd. (Israel) | Development agreement/Bio-Technology's development technologies | $20 |
Bio-Technology will develop and manufacture generic recombinant therapeutic products; Teva will pay up to $20M for product rights and milestone payments (10/99) |
Boston Life Sciences Inc. (BLSI) | Pfizer Inc. (NYSE:PFE) |
Development and license agreement/Boston Life's C-Maf technology | ND | Pfizer will screen its small-molecule collection for potential inhibitors of C-Maf to develop a small-molecule therapeutic for allergies and asthma; Boston Life will receive an undisclosed initial payment and royalties on eventual sales of any product resulting from the collaboration (9/99) |
Caliper Technologies Corp.* |
Eli Lilly and Co. (NYSE:LLY) | License agreement/Caliper's high-throughput screening technology access program |
ND |
Eli Lilly will have access to high-throughput screening technologies and products based on Caliper's LabChip microfluidics platform; Lilly will participate in the development of successive generations of the LabChip technology; financial details ND (8/99) |
Cambridge Antibody Technology (UK; LSE:CAT) | AstraZeneca Group plc (UK; NYSE:AZN) | Research collaboration/Cambridge's ProAb and ProxiMol platform technologies |
ND | Cambridge will use its ProAb technology to isolate and provide antibody-based research reagents specific for cell-surface receptors and intracellular targets provided by AstraZeneca; Cambridge will use its ProxiMol technology to generate biologically active antibodies to explore the function of a number of receptors; Cambridge will receive revenues from AstraZeneca and will retain all rights to develop and commercialize any antibodies generated from the collaboration (9/99) |
Celera Genomics(NYSE:CRA) |
Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France; NYSE:RP) |
Gene discovery agreement/Celera's GeneTag technology |
ND | Celera will identify therapeutic targets for various diseases by applying its GeneTag technology to Rhone-Poulenc's disease model systems; Rhone-Poulenc will pay up-front fees, milestones and royalties upon commercialization of any drugs resulting from the agreement; Rhone-Poulenc has the option to access Celera's capabilities for full-length cDNA cloning and functional characterization of candidate genes; financial details ND (7/99) |
Cell Pathways Inc. (CLPA) | Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France; NYSE:RP) |
Clinical trial collaboration/Cell Pathways' Aptosyn and Rhone-Poulenc's Taxotere |
ND |
The companies will collaborate in clinical trials investigating the therapeutic potential of Aptosyn (exisulind) in combination with Taxotere (docetaxel) in previously untreated non-small-cell lung cancer; each company will retain all marketing rights to its respective products; further details ND (9/99) |
Cerep SA(France; NM:CEREP) | Bristol Myers Squibb Co. (NYSE:BMY) |
R&D collaboration/Cerep's |
$43 |
The collaboration agreement spans BioPrint database five years, with an option for Bristol to terminate after three years; Bristol will have non-exclusive access to the BioPrint database and tools; Cerep will carry out high-throughput profiling of Bristol compounds currently in the lead development process; Cerep and Bristol will develop and share technologies related to assay miniaturization for compound profiling; research funding and potential milestone payments could exceed $43M, and will include an equity stake by Bristol of $3M; Cerep will receive royalties on any products resulting from the collaboration (7/99) |
Cetek Corp.* | Pharmacia & Upjohn Inc. (NYSE:PNU) | Screening agreement/Cetek's proprietary screening technology | ND | Cetek will develop assays for Pharmacia's targets and screen them against Pharmacia's compound libraries; further details ND (9/99) |
ChemBridge Corp.* |
F. Hoffmann-La Roche (Switzerland) |
Technology access agreement/ChemBridge's PharmaCore combinatorial lead discovery library | ND | ChemBridge entered a three-year agreement to provide Roche access to its PharmaCore library, which will be provided on a non-exclusive basis to all six Roche research centers in Switzerland, Germany, Japan, the UK and the U.S.; financial details ND (10/99) |
ChemRx (a subsididiary of Discovery Partners Int'l) |
The pharmaceutical division of Kirin Brewery Co. Ltd. (Japan) | Research agreement |
ND |
ChemRx will develop multiple classes of compounds for Kirin's lead optimization libraries on a fee-for-service, exclusive basis for screening in Kirin's internal assays; there are no milestone or royalty obligations under the agreement; further financial details ND (9/99) |
ChemRx (a subsidiary of Discovery Partners Int'l) |
Pharmacia & Upjohn (NYSE:PNU) | Research agreement |
ND | ChemRx will develop multiple classes of compounds for P&U's drug discovery and lead optimization libraries on a fee-for-service, exclusive basis for screening in P&U's internal assays; there are no milestone or royalty obligations under the agreement; further financial details ND (10/99) |
Chiron Corp. (CHIR) |
Abbott Laboratories (NYSE:ABT) |
License agreement/Chiron's hepatitis C patents |
ND |
Chiron will license its hepatitis C patent rights for use in nucleic acid diagnostics; the worldwide, semi-exclusive license grants Abbott the right to research, develop, manufacture and sell HCV nucleic acid probe products for in vitro diagnostics; Chiron will retain the right to grant limited additional licenses to others, and will receive an up-front license fee upon signing and a milestone payment upon first commercial sale of a licensed product; Chiron will also receive royalties on the sale of licensed products (9/99) |
Connetics Corp. (CNCT) |
Soltec Research Pty Ltd.* (Australia, a unit of F.H. Faulding & Co. Ltd.) | License agreement/Soltec's ketoconazole foam | ND | Connetics received exclusive, worldwide rights (exluding Australia and New Zealand) to develop, market and manufacture ketoconazole foam, a quick-break foam formulation of the antifungal dermatologic drug, ketoconazole; financial details ND (7/99) |
Corixa Corp. (CRXA) |
Zenyaku Kogyo Co. Ltd.* (Japan) | License, R&D agreement/Corixa's PVAC therapeutic | ND | Corixa and Zenyaku entered a multi-year license, research and development agreement for PVAC, a psoriasis immunotherapeutic; Zenyaku receives exclusive rights in Japan, while Corixa and its partner, Genesis Research and Development Corp., retain exclusive rights with respect to the rest of the world; Corixa will receive license fees, research funding and milestone payments based on successful clinical and commercial progress, as well as a royalty stream on future product sales; further financial details ND (8/99) |
deCODE Genetics * (Iceland) | Roche (Switzerland) | License agreement/deCODE's GeneMiner software | ND | Roche will license deCODE's GeneMiner bioinformatics software for the rapid identification of disease relevant genes in its internal programs; further details ND (9/99) |
Discovery Therapeutics Inc.* |
Fujisawa Healthcare Inc.* | Development and license agreement/Discovery's selective adenosine A1 agonist, DTI-0009 |
ND | Both companies will collaborate in the development of the injectable form of DTI-0009 for the treatment of cardiac conditions associated with abnormally high heart rates; Fujisawa will have exclusive North American development and marketing rights to an injectable form of the A1 agonist for the treatment of paroxysmal supraventricular tachycardia, and for rate control in atrial fibrillation and atrial flutter; additionally, Fujisawa will have exclusive marketing and promotion rights in the U.S. and Canada to all other injectable indications developed by Fujisawa for DT-0009 and certain back-up compounds; Discovery retains foreign rights to the injectable products; financial details ND (8/99) |
Exelixis Pharmaceuticals Inc.* | Bristol-Myers Squibb Co. (NYSE:BMY) |
Research collaboration/identification of validated targets |
ND | The companies entered a three year collaboration to identify novel validated targets for new medicines using model system genetics; Exelixis will use its proprietary technology to determine the molecular targets of compounds provided by Bristol; Bristol will provide Exelixis with research funding and additional payments subject to the achievement of research and commercialization milestones; Exelixis will contribute to the work of Bristol's internal department of applied genomics; the companies will exchange certain core technologies; Bristol will acquire Exelixis technology, including a sublicense to the patented P-element technology, tools to manipulate genes in Drosphila and C. elegans, and access to the Drosophila proprietary EST database, FlyTag; Exelixis will acquire BMS lead optimization tecnology (9/99) |
FibroGen Inc.* |
Taisho Pharmaceuetical Co. Ltd. (Japan) | Development agreement/human monoclonal antibodies | ND |
FibroGen and Taisho entered an agreement to develop and commercialize human monoclonal antibodies for the treatment of fibrotic kidney diseases; Taisho will provide funding in the form of equity purchases, benchmark payments and one-half of the global preclinical and clinical development costs out side the Pacific Rim, where Taisho will fund all the clinical and development costs; additionally, Taisho will pay FibroGen royalties on sales of therapeutic antibody products in Japan, China, Taiwan, Korea and the countries of Southeast Asia; FibroGen will retain commercialization rights in North America, Europe and the rest of the world (9/99) |
Gene Logic Inc. (GLGC) |
UCB Research Inc.* (a unit of UCB Pharma) |
Development agreement/Gene Logic's READS technology and Affymetrix Inc.'s GenChip probe arrays |
ND |
Gene Logic and UCB will jointly develop a custom gene expression database for the discovery of new drugs for asthma and allergies; the companies also will work through a joint research committee to evaluate potential therapeutic targets resulting from the collaboration; financial details ND (9/99) |
GeneTrace Systems Inc.* |
Berlex Laboratories Inc. (a subsidiary of Schering AG; Germany) |
Research collaboration/GeneTrace's gene expression technology | ND | GeneTrace will combine its gene expression technology with Berlex's chemical library compounds; GeneTrace will apply its technology to the study of a number of human cancer genes provided by Berlex; Berlex will pay GeneTrace an initiation fee and additional funds upon completion of specific milestones; financial terms ND (8/99) |
Genome Therapeutics Corp. (GENE) |
bioMerieux* (France) |
Technology access agreement /Genome's PathoGenome database |
$6.2 | bioMerieux purchased a subscription to Genome's microbial PathoGenome database as part of an alliance to develop, manufacture and sell in vitro diagnostic products for human clinical and industrial applications; Genome granted bioMerieux all rights in the area of pathogen genetics; bioMerieux paid an up-front technology access fee and made a $3.75M equity investment in Genome's common stock; in addition, bioMerieux will fund a research program for at least four years, subscribe to the PathoGenome database and pay royalties on future products; guaranteed first-year funding, including the equity investment is approximately $6.2M; additional terms ND (10/99) |
Igen International Inc. (IGEN) | Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France; NYSE:RP) |
Technology access agreement/Igen's M-Series high-throughput screening system | ND | Rhone-Poulenc received access to Igen's M-Series screening systems for use in its drug screening projects; further details ND (7/99) |
Insite Vision Inc. (AMEX:ISV) |
SSP Co. Ltd.* (Japan) | License agreement/Insite's AquaSite treatment for dry eye |
ND |
Insite signed an exclusive licensing agreement granting the Japanese rights to AquaSite to SSP; further details ND (8/99) |
Isis Pharmaceuticals (ISIP) |
Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France; NYSE:RP) |
Research collaboration/Isis' Antisense target validation technology |
ND |
Isis and RPR signed a three-year collaboration agreement to assess genes identified within RPR's genomics programs using Isis' target validation technology; RPR will provide Isis with sequence information on a number of novel gene targets, with the option to expand the number provided; Isis will design optimized antisense inhibitors for these targets, which RPR will use to identify the function of the gene and prioritize the gene targets for development; Isis will develop antisense inhibitors for the targets provided by RPR; RPR will pay Isis research fees and milestone payments based on the success of the collaboration; further financial details ND (9/99) |
Lexicon Genetics Inc.* |
The Parke-Davis pharmaceutical division of Warner-Lambert Co. (NYSE:WLA) |
Research agreement/Lexicon's knockout mice |
ND |
Lexicon and Warner entered an agreement for the rapid engineering of custom knockout mice; Lexicon will produce an undisclosed number of knockout mice using patented technologies in homologous recombination; financial details ND (7/99) |
LifeCell Corp. (LIFC) | Pharmacia & Upjohn (NYSE:PNU) | Research collaboration/LifeCell's ThromboSol |
ND | LifeCell will collaborate with P&U and the University of Texas M.D. Anderson Cancer Center to evaluate ThromboSol for the extended storage of platelets; further details ND (7/99) |
Ligand Pharmaceueticals Inc. (LGND) | The Parke-Davis pharmaceutical division of Warner-Lamber Co. |
R&D, license agreement/Estrogen receptor diseases |
$13 | Ligand and Parke will collaborate on the discovery, characterization, design and development of small molecule comounds for the treatment and prevention of diseases mediated through the estrogen receptor; Ligand may receive up to $13M in research funding through September 2002, as well as undisclosed future product milestone payments and royalties; ParkeDavis will fund the costs of developing and marketing compounds selected from the collaboration, and will be granted worldwide rights to manufacture and sell any products resulting from the collaboration; Ligand will be entitled to milestones at various stages of each compound's development, and upon the marketing of a product, will receive royalties on net sales on a product-by-product basis (9/99) |
The Liposome Co. Inc. (LIPO) |
Bristol-Myers Squibb Co. (NYSE:BMY) |
Clinical trial collaboration/Liposome's Evacet and Bristol's Taxol |
ND |
Liposome and Bristol will collaborate in clinical trials designed to evaluate the safety and efficacy of Evacet in combination with Taxol (paclitaxel) for the treatment of metastatic breast cancer; financial details ND (8/99) |
Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France; NYSE:RP) | Clinical trial collaboration/Liposome's Evacet and RPR's Taxotere |
ND |
Liposome and RPR will collaborate in clinical trials designed to evaluate the safety and efficacy of Evacet in combination with Taxotere (docetaxel) for the treatment of metastatic breast cancer; financial details ND (8/99) | |
Molecumetics Ltd. (a subsidiary of Tredegar Corp.; NYSE:TG) |
Pharmacia & Upjohn Co. (NYSE:PNU) |
Research collaboration/Molecumetics' SMART Library technology | ND | Molecumetics and P&U entered a research collaboration to identify and develop orally active modulators of caspases; Molecumetics will use its SMART Library technology to optimize lead compounds; P&U will carry out in vivo testing and all preclinical and clinical development activities; Molecumetics will grant P&U worldwide exclusive rights to develop and commercialize the resulting compounds; Molecumetics will receive research funding, milestone payments and royalties from the sales of potential products resulting from the collaboration (9/99) |
NaPro Biotherapeutics Inc. (NPRO) |
Abbott Laboratories (NYSE:ABT) |
R&D collaboration/anticancer therapeutics |
ND | NaPro and Abbott entered a longterm collaborative agreement to develop and commercialize one or more formulations of paclitaxel for the treatment of a variety of cancer indications; the agreement covers the U.S. and Canada; NaPro will supply the bulk drug and will jointly conduct the clinical trials with Abbott; Abbott will be responsible for the formulation, regulatory filings, marketing and sale of the finished product; NaPro will license to Abbott its U.S. paclitaxel-related patents, issued and pending, plus any foreign-issued patents which may apply within the U.S. and Canada; NaPro will receive funding from Abbott in the form of development and marketing milestone payments, a secured loan and an equity investment; Abbott will purchase bulk drug from NaPro and will pay royalties to NaPro from the sale of resulting products (7/99) |
Nortran Pharmaceuticals Inc. (Canada; OTC BB:NTRDF; VSE: NRT) |
Hoechst Marion Roussel (the pharmaceutical subsidiary of Hoechst AG) |
Research collaboration/investigational anti-arrhythmic compounds |
ND |
Nortran and Hoechst will test investigational antiarrhythmic compounds of both companies using their electrophysiological models and other preclinical tests; further details ND (8/99) |
Neurocrine Biosciences Inc. (NBIX) |
DuPont Pharmaceuticals Co. and Janssen Pharmaceutica (a subsidiary of Johnson & Johnson; NYSE:JNJ) |
License agreement |
ND | The companies entered a three-way licensing agreement of patents and patent applications relating to a series of small-molecule CRF receptor antagonist compounds; Neurocrine and Janssen receive exclusive rights to a subset of DuPont's CRF antagonist compounds jointly developed by those two companies; Janssen and DuPont agreed to certain milestone payments and royalties on product sales; Neurocrine licensed to DuPont exclusive rights to a subset of CRF receptor antagonist compounds independently developed by Neurocrine; DuPont will make milestone payments to Neurocrine based on the achievement of certain developmental and regulatory goals, and royalty payments based on product sales (9/99) |
OSI Pharmaceuticals Inc. (OSIP) |
Tanabe Seiyaku Co. Ltd.* (Japan) |
R&D collaboration/small-molecule drugs for treatment of Type 2 diabetes mellitus |
ND |
OSI formed a strategic partnership with Tanabe to discover and develop small-molecule drugs for the treatment of Type 2 diabetes mellitus; OSI will receive an upfront fee, support for a four-year funded research program, and milestone, success payments and royalties on successful product development; successful development could result in over $30M of milestone payments and success fees, over and above royalties, for each target in the multi-target program (9/99) |
Paratek Pharmaceuticals Inc.* |
Glaxo Wellcome plc (NYSE:GLX) |
R&D collaboration/antibiotic targeting multiple antibiotic resistant bacteria |
ND | Paratek and Glaxo entered a collaboration to develop and commercialize new antibiotics targeting multiple antibiotic-resistant bacteria; the agreement includes equity investments, research support, milestone payments and royalties; further details ND (7/99) |
Pharmacopeia Inc. (PCOP) |
Hoffmann-La Roche Inc. (a member of the Roche group) |
Research collaboration/Pharmacopeia's Melanocortin-4 (MC-4) |
ND |
Pharmacopeia and Roche entered a research collaboration focusing on small-molecule agonists for MC-4; Roche will provide Pharmacopeia with research funding to pursue further chemical optimization of the lead compounds identified by Pharmacopeia; the two companies will collaborate in an effort to identify a clinical candidate to be developed and commercialized by Roche; financial details ND (10/99) |
Pharmasset Ltd.* | DuPont Pharmaceuticals Co. |
R&D collaboration/HIV and hepatitis B antiviral compounds |
$30 |
Pharmasset and DuPont entered a collaboration to create and identify novel nucleoside reverse transcriptase inhibitors to be developed and commercialized by DuPont; the agreement includes an equity investment, up-front payment, research support, milestones and royalties on products resulting from the collaboration (9/99) |
PolyMasc Pharmaceuticals plc (UK; acquired by Valentis Inc.; VLTS) |
The pharmaceutical division of Bayer Corp. (Germany) | Research agreement/PolyMasc's ProtoMasc technology |
ND |
Bayer will fund a feasibility study on the development of factor VIII using PolyMasc's ProtoMasc technology in order for Bayer to determine whether to enter a broader agreement leading to clinical and commercial development of a chemically modified factor VIII; financial details ND (8/99) |
Protein Design Labs Inc. (PDLI) |
ND | License agreement/PDL's antibody humanization patents | ND |
PDL signed a patent license agreement with a major, undisclosed pharmaceutical company for certain non-exclusive rights under PDL's antibody humanization patents to an antibody in clinical development; PDL will receive a non-refundable, non-creditable fee, annual maintenance fees and potential royalties on sales of the antibody; further details ND (9/99) |
Protein Design Labs Inc. (PDLI) | SmithKline Beecham (NYSE:SBH) |
License agreement/SmithKline's humanized antibody to interleukin-4 (anti-IL-4) and PDL's antibody humanization patents for its humanized antibody to interleukin-5 (anti-IL-5) |
ND |
PDL obtained a license to SB's anti-IL-4; PDL granted an exclusive license under its humanization patents to SB for anti-IL-5; PDL will complete a Phase I trial for anti-IL-4 and conduct Phase II trials in asthma patients; SB will manufacture the antibody for the trials; PDL will be entitled to exclusive, worldwide development, marketing and sales rights to the anti-IL-4 antibody unless SB pays an opt-in fee at the end of Phase II clinical development; if SB elects to participate, the two companies will share future development costs and profits at an agreed-upon ratio; PDL may also receive certain co-promotion rights in the U.S. (9/99) |
Quark Biotech Inc.* | Sankyo Co. Ltd.* (Japan) | Research and license agreement/Quark's gene discovery technology | ND | Quark will use its gene discovery technology to identify key genes and pathways responsible for apoptosis of particular cells and tissues caused by certain autoimmune disease, identify candidates for drug development, and eventually commence clinical testing for selected therapeutic candidates; Sankyo will have exclusive rights to market products resulting from the collaboration; Quark will be entitled to research and development payments, milestone payments and royalties (9/99) |
Sangamo Biosciences Inc.* |
Schering AG (Germany) |
Research agreement/Sangamo's Universal GeneTools technology | ND | Sangamo and Schering signed a collaborative research agreement under which Sangamo will provide specific Universal GeneTools to Schering for evaluation in its research programs; further details ND (8/99) |
Sequitur Inc.* | Pharmacia & Upjohn (NYSE:PNU) |
Technology access agreement/Sequitur's antisense functional genomics technology |
ND | Sequitur and P&U signed a multi-year agreement under which P&U will have access to Sequitur's antisense functional genomics technology; further details ND (9/99) |
Sequitur Inc.* |
Searle (the pharmaceutical division of Monsanto Co.; NYSE:MTC) | Technology access agreement/Sequitur's antisense functional genomics technology |
ND |
Sequitur and Searle signed a multi-year agreement under which Searle will have access to Sequitur's antisense functional genomics technology; the agreement provides for the supply of Sequitur's antisense compounds, sequence selection and cellular delivery vehicles to Searle, as well as collaborative research to be performed at Sequitur; Searle will pay research support, antisense material charges and licensing fees (10/99) |
Sibia Neurosciences Inc. (SIBI) | Pharmacia & Upjohn (NYSE:PNU) |
License agreement/Sibia's transcription-based assay patent portfolio |
ND | Sibia and P&U entered a nonexclusive license agreement for Sibia's transcription-based assay patent portfolio; P&U and its affiliates receive a worldwide license to drug discovery technology that uses transcription-based assays for identifying compounds that modulate cell surface protein activity; Sibia will receive annual maintenance payments, as well as royalties on sales of any compounds resulting from the agreement (7/99) |
SkyePharma plc (UK) |
SmithKline Beecham (NYSE:SBH) |
Development and licensing agreement/SB's Requip and SkyePharma's Geomatrix oral delivery technology |
$8 | SB and SkyePharma entered a development and licensing agreement for a once-daily version of SB's anti-Parkinsonian drug Requip (ropinirole), using SkyePharma's Geomatrix oral delivery technology; SkyePharma will be responsible for all development activities up to regulatory filing in collaboration with SB; SB will make an equity investment of $8M in SkyePharma; SkyePharma will receive milestone payments at intervals up to product approval, including an up-front payment; upon commercialization of once-daily Requip, SkyePharma will receive royalties on product sales (9/99) |
Stem Cell Sciences* (Australia) |
Rhone-Poulenc Rorer (the pharmaceutical subsidiary of Rhone-Poulenc SA; France; NYSE:RP) | Gene and drug screening collaboration/Stem Cell's gene screening technology |
$1.5 |
Stem Cell will provide RPR with its gene screening technology to functionally validate neuroprotective genes and genetically engineered cells for use in its Alzheimer's drug discovery program; RPR will pay Stem Cell $1.5M in up-front and milestone payments in return for a non-exclusive license to use Stem Cell's technology; further details ND (8/99) |
Targeted Genetics Corp. (TGEN) |
Elan Corp. plc (NYSE:ELN) |
Development agreement/gene delivery technology | $22 |
Targeted and Elan signed definitive agreements to form a new subsidiary of Targeted Genetics, to be called Emerald Gene Systems, for the enhanced delivery of therapeutic genes; Targeted will own 81% of the new company, subject to completion of appropriate trademark searches; Elan will make an initial $5M investment in Targeted common stock at a premium to market price, and will purchase an additional $5M of common stock at a premium to market one year from the date of the agreements; additionally, Elan will purchase $12M of Targeted convertible exchangeable preferred stock; Elan has the right to either convert the preferred stock into additional common shares or exhange it for increased ownership in Emerald to 50% (7/99) |
Third Wave Technologies Inc.* |
Parke-Davis pharmaceutical division of Warner-Lambert Co. |
Technology access agreement/Third Wave's Invader assay portfolio |
ND |
Third Wave will provide Warner with a portfolio of Invader assays for evaluation in genotyping and gene expression applications; Third Wave will own improvements to its technology and will receive exclusive access to discoveries made using the Invader assays for diagnostic applications; financial details ND (9/99) |
Valentis Inc. (VLTS) |
Boehringer Ingelheim International GmbH* (Germany) |
Research collaboration/Valentis' delivery and expression systems and Boehringer's proprietary genes in animal models of rheumatoid arthritis (RA) |
ND | The two companies will conduct evaluations of Valentis' delivery and expression systems in combination with Boehringer's proprietary genes in animal models of RA; Boehringer will provide research support to Valentis for up to 15 months for work performed under the collaboration; financial details ND (9/99) |
XTL Biopharmaceuticals Ltd.* |
Eli Lilly & Co. (NYSE:LLY) |
Research agreement/XTL's model for hepatitis | ND | XTL will test a Lilly drug candidate in its proprietary animal model for hepatitis C; further details ND (9/99) |
Zycos Inc.* | Pasteur Merieux Connaught (a unit of Rhone-Poulenc SA; France; NYSE:RP) |
R&D collaboration/Zycos' Epiquest antigen database |
ND | Zycos and Pasteur will collaborate to identify antigens that may play a role in fighting cancer using Zycos' epitope discovery program; further details ND (8/99) |
Notes: | ||||
#This chart contains information on new agreements, covering the time between 7/1/99 and 10/15/99. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the 11/22/99 issue of BioWorld Financial Watch. The chart above also does not include any collaborations that involve agricultural product development (which are covered periodically in this publication). A chart covering modified agreements and terminated agreements between big pharma and biotech companies for the same time period (7/1/99-10/15/99) will also appear in the 11/22/99 issue of BioWorld Financial Watch. | ||||
Unless otherwise noted, the trading symbols listed are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; NM = Nouveau Marche; OTC BB = Over The Counter Bulletin Board | ||||
ND = Not disclosed, reported and/or available | ||||
* Private companies are indicated with an asterisk. | ||||
Conversion rate of DM1 = US$0.53 | ||||
To read more on related topics, click on one of the words below.